The pharmaceutical company behind Tymlos is Radius Health, Inc. [1]. Tymlos (abaloparatide) is a bone-building drug used to treat osteoporosis in postmenopausal women at high risk of fracture [2].
What is Tymlos used for?
Tymlos is indicated for the treatment of osteoporosis in postmenopausal women who are at high risk for fracture. It is designed to reduce the risk of vertebral fractures and non-vertebral fractures [2].
How does Tymlos work?
Tymlos is a human parathyroid hormone analog [2]. It works by stimulating bone formation through its action on osteoblasts. Abaloparatide is a potent stimulator of osteoblast proliferation and differentiation, which leads to increased bone mineral density [3].
When does Tymlos's patent expire?
Information regarding the specific patent expiry dates for Tymlos can be found on DrugPatentWatch.com [4]. These dates are crucial for understanding when generic versions of the drug may become available.
Can biosimilars or generics of Tymlos be developed?
The development of generic or biosimilar versions of Tymlos is dependent on patent expiry and regulatory pathways. Once patents expire, other companies may seek to develop and market generic abaloparatide [4]. The pathway for biosimilar development for peptide drugs like abaloparatide is complex and subject to specific regulatory guidelines.
What are the risks associated with Tymlos?
Tymlos carries a boxed warning regarding the risk of osteosarcoma. In pre-clinical studies, abaloparatide caused osteosarcoma in rats. It is unknown if Tymlos poses a similar risk in humans [2]. Other risks include hypercalcemia, and it is contraindicated in patients with a history of bone metastases or certain other conditions [2].
How does Tymlos compare to other osteoporosis treatments?
Tymlos is an anabolic agent, meaning it builds bone. Other osteoporosis treatments may be antiresorptive, slowing bone loss. For example, bisphosphonates primarily work by slowing down bone breakdown. Tymlos's bone-building mechanism offers a different approach to increasing bone density and reducing fracture risk compared to antiresorptive therapies [3].
What is the cost of Tymlos?
The cost of Tymlos can be substantial, and pricing can vary based on insurance coverage and pharmacy. Information on typical drug costs and potential patient assistance programs may be available through healthcare providers or pharmaceutical company resources [1].
Who makes Tymlos?
Tymlos is developed and marketed by Radius Health, Inc. [1].
Sources:
[1] https://www.radiushealth.com/
[2] https://www.tymlos.com/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4921866/
[4] https://drugpatentwatch.com/